Merck announced Health Canada has approved Brenzys® (biosimilar etanercept) for four new indications:
-
adult patients with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy
-
pediatric patients ages 4 to 17 years with chronic severe PsO who are candidates for systemic therapy or phototherapy
-
reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis and improving physical function in adult patients with psoriatic arthritis (PsA)
-
reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 to 17 years